报价延迟最少15分钟:2026/05/19 19:37 EDT
盘后时段
|
||||
|
307.04 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
303.93
|
|
|
| 价值评估 |
|
盈利(现时/预测)
7.48/9.25
|
|
企业价值
21.80B
|
| 资产负债 |
|
每股账面净值
42.33
|
| 现金流量 |
|
现金流量率
0.03
|
| 损益表 |
|
收益
3.07B
|
|
每股收益
41.42
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States. |
